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Summary: 
In a nationwide study of 3,818 charts from patients with fatal COVID-19, we found that 
geographical differences in Dipeptidyl peptidase 4 (DPP4) inhibitors use did not correlate with 
diabetes prevalence among COVID-19 deaths, thus not  supporting the hypothesis of a clinically 
relevant involvement of DPP4 in COVID-19 development and progression. 
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1. Introduction 
Dipeptidyl peptidase 4 (DPP4) is a serine exopeptidase which regulates immune responses by 
acting as a co-stimulatory molecule on T-cells [1]. It is a pharmacological target of DPP4 
inhibitors (DPP4i), a class of drugs widely used for the management of type 2 diabetes (T2D). It 
has been proposed that DPP4 might sterically interact with the S1 domain of the SARS-CoV-2 
spike glycoprotein [2]. Moreover, DPP4i modulate inflammation by suppressing Th17 activity 
and proinflammatory cytokines [3-5], two features of severe COVID-19 [6, 7]. In an 
experimental model of Acute Respiratory Distress Syndrome (ARDS), a main cause of COVID-
19 death, DPP4 inhibition alleviated histological findings of lung injury by inhibiting 
proinflammatory cytokines IL-1β, TNFα, and IL-6 [8]. Therefore, DPP4 inhibition may have a 
role in limiting two steps of COVID-19 immunopathogenesis: 1) by altering a potential SARS-
CoV-2/DPP4 interaction; 2) by halting disease progression towards hyperinflammation. Under 
the hypothesis that treatment with DPP4i could prevent COVID-19 progression in subjects with 
diabetes, the aim of this analysis is to examine the association between DPP4i use among those 
with diabetes and COVID-19 deaths across regions of Italy during the pandemic. 
2. Materials and methods
A COVID-19 surveillance system was launched by the Italian National Institute of Health 
(Istituto Superiore di Sanità [ISS]) in line with the the Ministry of Health circular published in 
February 2020. Medical charts of people who died from COVID-19 in Italy were randomly 
sampled from the 21 Italian sanitary districts proportional to the total number of COVID-19 
deaths which occurred in each district (the higher the number of deaths in one district, the 
higher was the number of medical charts reviewed in that district). As of the time of this 
analysis (June 17th, 2020) no medical charts were available from Valle D’Aosta, therefore, 
relevant data from only 20 Sanitary districts were provided by the ISS. Demographics of the 
population living in each district and diabetes prevalence in each region were obtained from the 
2019 Italian statistical yearbook by the ISTAT [9]. Drug use was estimated for each sanitary 
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district using data provided by IQVIA®. An additional primary source (Osservatorio per la 
Salute, Autonomous Province of Bolzano) that had access to all cases of COVID-19 deaths 
registered to April 27th, 2020 (n=269), was used to validate data about DPP4i use in the general 
population and among patients with COVID-19 (Supplementary Material). As DPP4i are only 
available through specialist in a monitored process these data are likely more accurate than 
other drug use reports.  Exposure in the population is expressed as the proportion of daily DPP4i 
units sold per 100 patients per year assuming 100% compliance. Spearman’s rank correlation 
test was used to evaluate linear relationships between continuous variables. The analysis 
conducted on the 20 sanitary districts provided 80% power to detect an effect size of 0.55. Type 
I error threshold was set at two-tailed p<0.05. Stata/IC 12.1 and Prism 8.0d were used for 
analysis and figures.
3. Results
A sample of 3,818 medical charts from individuals who died of COVID-19 had been reviewed 
by the ISS by the time of this analysis; 467 were excluded due to unknown diabetes status 
resulting 87.8% (n=3351) being used in the analysis. As the number of COVID-19 deaths varied 
by region,  the ISS sampling algorithm dictates the number of medical charts reviewed from 
each sanitary district: from Lombardy n=1,813 were sampled (54.1% of deaths), Emilia 
Romagna (n=507; 15.21%) and Veneto (n=200; 6.0%). The median [IQR] number of medical 
charts reviewed in each region was 41 [8-108].
Of the charts reviewed of individuals who died from COVID-19, 1,089 (32.5%) patients had 
diabetes. Diabetes prevalence among COVID-19 deaths varied substantially by the districts: the 
highest was in Trento (54.8%), then Molise (50.0%), Sardinia (40.0%), while the lowest was in 
Calabria (16.7%) and Abruzzo (12.5%). No cases of diabetes were registered among the seven 
medical charts of patients died in Umbria. Deaths from COVID-19 were not associated with 
diabetes prevalence across the individual districts used in this analysis. (rho=0.153, p=0.52). 
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The total number of medical charts reviewed in each district did not correlate with the 
prevalence of diabetes among COVID-19 deaths (rho=0.002, p=0.99).
The median percentage use of DPP4i among diabetic people in the sanitary districts was 11.4% 
[10.2-12.5]; Sicily was the lowest (5.7%), while Bolzano and Sardinia showed the highest 
percentages (16.9% and 16.8%, respectively) (Table S1). The percentage use of DPP4i in each 
district was unrelated to diabetes prevalence among those who died from COVID-19 (-0.247, 
p=0.29; Figure 1). No significant differences in the use of DPP4i were found between alive and 
deceased T2D patients with COVID-19 in the Autonomous Province of Bolzano according to 
the data from “Osservatorio per la Salute” (25/149 [16.8%] vs 5/44 [11.4%], repsectively, 
p=0.48; Table S2).
4. Discussion 
In this study, over one third of individuals who died of COVID-19 had diabetes. Geographical 
differences in DPP4i use did not correlate with diabetes prevalence among COVID-19 deaths.
Our data extend findings from two recent reports that evaluated the association between DPP4i 
treatment and COVID-19 fatality. In an Italian case-control study involving 85 T2D individuals 
hospitalized for COVID-19, previous DPP4i treatment (nine patients) was unrelated to COVID-
19 death [10]. In the CORONADO study, a larger, nationwide observational study of 1,317 
diabetic people hospitalized for COVID-19, DPP4i treatment before admission (285 subjects) 
did not improve the primary outcome (invasive respiratory support or death within seven days 
from admission) [11]. However, the small sample size stands out as major limitation in the 
former, while the latter study was not specifically designed to assess the relationship between 
DPP4i and COVID-19. Main strengths of our study include the large number of cases assessed 
nationwide and the use of hard endpoint which can be measured unambiguously. Due to its 
ecologic nature, our study is limited to the biases inherent these types of studies, and by the lack 
of data on glucose control and other comorbidities. 
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In conclusion, our findings suggest that pharmacological inhibition of DPP4 may not have a role 
in preventing SARS-CoV-2 infection and/or COVID-19 progression. 
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Figure 1 – Relationship between estimated overall DPP4i prevalence use in individuals 




Table S1 – Prevalence of diabetes in the general population (presented in ascending order, as estimated by ISTAT) and 
among individuals died of COVID-19 (retrieved from medical chart review by ISS) and estimated percentage use of 
DPP4i among individuals with diabetes in each Italian region and Autonomous Province*.
Region Diabetes Prevalence (%) DPP4i use (%)
Overall 
(ISTAT 2019)
Among COVID-19 deaths (ISS)
A. P. Bolzano 2.8 30.0 16.9
A. P. Trento 4.4 54.8 9.00
Veneto 4.5 39.5 12.0
Lombardy 4.6 32.0 12.5
Piedmont 4.6 29.7 12.4
Sardinia 4.7 40.0 16.8
Marche 4.9 23.1 14.5
Tuscany 5.1 29.7 11.8
Emilia Romagna 5.3 32.0 10.8
Friuli Venezia Giulia 5.3 31.7 9.8
Liguria 5.6 36.2 8.8
Lazio 5.8 36.2 12.2
Umbria 6.4 0.00 11.5
Campania 6.5 35.7 11.2
Sicily 6.5 36.4 5.7
Molise 6.9 50.0 10.5
Basilicata 7.0 33.3 10.7
Puglia 7.1 38.5 11.3
Abruzzo 7.5 12.5 8.2
Calabria 8.2 16.7 12.9
Table Legend: ISTAT, National Institute of Statistics, ISS, Istituto Superiore di Sanità. *Data from Valle D’Aosta regions were not available at 
the time the present analysis was performed.
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Table S2 – Prevalence use of DPP4i in the general population of patients with type 2 diabetes (T2D) and in those with SARS-CoV-2 
infection according to the COVID-19 survival outcome as of April 27th, 2020 in the Autonomous Province of Bolzano.
T2D (overall) T2D with COVID-19† Alive T2D with 
COVID-19
Deceased T2D with 
COVID-19
N (m/f) 20,830 (11.244/9.586) 193 (106/87) 149 (77/72) 44 (29/15)
Age (m/f), years 72.3±12.8 (70.8±11.9/74.1±13.4)
76.711.8
(73.811.0/80.311.7)




DPP4i treatment#, n (%) 3,069 (14.7) 30 (15.5) 25 (16.8) 5 (11.4)
Other glucose-lowering 
medications§, n (%) 12.709 (61.0) 115 (59.6) 83 (55.7) 32 (72.7)
Diet and other TLC, n (%) 5.052 (24.3) 48 (24.9) 41 (27.5) 7 (15.9)
Table Legend: TLC, therapeutic lifestyle changes; T2D, type 2 diabetes; #Alone, in fixed combination with metformin, pioglitazone, SGLT2i or in combination with other 




Estimate of DPP4i prevalence use
Data about DPP4i use were estimated for each sanitary district upon data provided by IQVIA®.
IQVIA® provided data about the number of sitagliptin (alone or in the combination tablet with 
metformin) packages sold from January 1st, 2019 to December 31st, 2019 in each sanitary 
district. The sitagliptin market share (percentage of the total DPP4i sales) in each sanitary 
district was also provided. 
Considering that each package covers 28 days of therapy with sitagliptin or 
sitagliptin+metformin (when prescribed at full dosage), the total number of patients on 
sitagliptin (which corresponds to the total number of daily therapeutic sitagliptin units: 1 tablet 
for sitagliptin alone and 2 tablets for sitagliptin + metformin) in each sanitary district ( ) was 𝑋𝑠𝑑
estimated as follows: 
 (1)     𝑋𝑠𝑑 =
𝑁𝑠𝑑 ×  28 𝑑𝑎𝑦𝑠
365 𝑑𝑎𝑦𝑠
where N is the total number of packages in 2019 and sd is the sanitary district. 
The total number of patients on DPP4i in each district ( ) was then calculated as follows: 𝐷𝑠𝑑
(2)   𝐷𝑠𝑑 = 𝑋𝑠𝑑 ×  𝑀𝑆𝑠𝑑
where MS is the market share of sitagliptin, as provided by IQVIA®
The proportion of patients with diabetes using DPP4i in each sanitary district was then 
calculated as follows:




where P is the total number of patients with diabetes.
Validation of Bolzano and Trento data from additional primary source
The "on-field” analysis provided by the “Osservatorio per la Salute” of the Autonomous Province 
of Bolzano resulted from the combination of the following sources of information: (1) The SARS-
CoV-2 infection pharyngeal nose swabs provincial database; (2) the medical records of  
individuals deceased because of COVID-19 as of April 27th, 2020; (3) The South-Tyrol Diabetes 
Registry, developed according to a redundant data inflow comprising information on diabetes 
medication use by linkage with the provincial pharmacological service (as of December 31st, 
2019), disease-specific exemption code, hospitalization for diabetes or diabetes diagnosis 
recorded in the electronic hospital discharge coding system, laboratory tests (hemoglobin A1c, 
fasting plasma glucose and/or oral glucose tolerance test, according to most recent ADA/EASD 
diagnostic criteria) and/or registered visits and diabetes classifications in the electronic medical 
records of the adult and pediatric local Diabetes Centers. Treatment with DPP4i was ascertained 
according to the Anatomical Therapeutic Chemical classification codes. Gestational diabetes, 
other forms of temporary dysglycemia (i.e. iatrogenic diabetes) and other rare diabetes subtypes 
were excluded from all analyses.
